Rhenman & Partners Asset Management AB Has $18.16 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Rhenman & Partners Asset Management AB raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 43.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 45,675 shares of the biopharmaceutical company’s stock after purchasing an additional 13,800 shares during the period. Alnylam Pharmaceuticals accounts for about 1.7% of Rhenman & Partners Asset Management AB’s holdings, making the stock its 19th biggest position. Rhenman & Partners Asset Management AB’s holdings in Alnylam Pharmaceuticals were worth $18,163,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of ALNY. HM Payson & Co. acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $27,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. Ameriflex Group Inc. bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $32,000. Manchester Capital Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 600.0% during the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 72 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the transaction, the insider owned 9,443 shares in the company, valued at $3,120,156.06. This trade represents a 19.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares in the company, valued at $473,302.76. This trade represents a 70.77% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,740 shares of company stock worth $2,420,214 in the last quarter. Insiders own 0.86% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Citigroup assumed coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They set a “buy” rating and a $380.00 price target on the stock. Chardan Capital restated a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Truist Financial cut their price target on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Finally, HC Wainwright restated a “buy” rating and set a $510.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, June 4th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $463.13.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $282.85 on Friday. The company has a market capitalization of $37.76 billion, a PE ratio of 77.28 and a beta of 0.29. Alnylam Pharmaceuticals, Inc. has a one year low of $281.77 and a one year high of $495.55. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The company’s fifty day moving average price is $304.31 and its 200 day moving average price is $343.68.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business’s quarterly revenue was up 96.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.44) EPS. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.